“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Progressing towards the development of
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Lupin appoints Sreeji Gopinathan as Chief Information Officer
Mumbai, October 03, 2019: Pharma major Lupin Limited announced today the appointment of Sreeji Gopinathan as Chief Information Officer (CIO). He will lead the IT function for Lupin globally, based in Mumbai.
Sreeji brings to Lupin over 20 years of significant domain expertise and global experience. Most recently, Sreeji was with Reckitt Benckiser. Prior to that, he was associated with Philips, Procter & Gamble, ISRO and Asea Brown Boveri. Sreeji holds a Master’s degree in Business Administration from the University of Edinburgh, UK and B. Tech (Applied Electronics and Instrumentation) from the University of Kerala.
Commenting on the appointment, Nilesh Gupta – Managing Director, Lupin said, “We have built a very solid Information Technology foundation, whether it pertains to our manufacturing operations, our sales operations or our HR processes. With Sreeji’s joining, Lupin’s IT function will be further strengthened. With his substantial experience and ability to closely work with businesses, he will expand and invigorate our initiatives in digitization, process automation, data management and analytics which will eventually help improve business results.”
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded
Lupin is the 8th largest generics pharmaceutical company by revenues (31st Mar 2019, Bloomberg LTM) respectively. The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT Jun 2019); 3 rd largest Indian pharmaceutical company by global revenues (31st Mar 2019, Bloomberg LTM); 5th largest generic pharmaceutical player in Japan and 6th largest company in the Indian Pharmaceutical Market (IQVIA MAT Jun 2019).
For the financial year ended 31st March, 2019, Lupin’s Consolidated sales and Net profits were at Rs. 163,694 million (USD 2.34 billion) and Rs. 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries please contact –
Head – Investor Relations and M&A / Corporate Communications